Novo Nordisk CEO on disappointing Rybelsus sales: Influenced by lockdown

Sales of diabetes tablet Rybelsus have been significantly lower than what analysts had predicted, according to Wednesday’s quarterly report from Novo Nordisk. CEO Lars Fruergaard Jørgensen thinks this is due to lockdowns.

Photo: Stine Bidstrup/ERH

In spite of GLP-1 sales increasing overall, Novo Nordisk's diabetes tablet Rybelsus sold for significantly less than what industry analysts had forecast for the first three months of the year.

Based on estimates gathered by Novo Nordisk from around 28 analysts before the publication of the report, Rybelsus was predicted to surpass DKK 1bn sales in this year's first quarter.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs